NCT02476058 - A Safety, Efficacy and Biomarker Study of JNJ-42847922 in Participants With Major Depressive Disorder | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 11, 2015

Primary Completion Date

January 4, 2016

Study Completion Date

January 4, 2016

Conditions

Major Depressive Disorder

Interventions

DRUG

JNJ-42847922

JNJ-428479, 20 milligram (mg) capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.

DRUG

Diphenhydramine

Diphenhydramine 25 mg capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.

DRUG

Placebo

Matching placebo (capsules containing neutral pellets), orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.

Trial Locations (7)

Unknown

Aalst

Brussels

Duffel

Berlin

Hamburg

Schwerin

Leiden